Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

BackgroundEpidemiological studies increasingly associate several adult vaccinations with lower risk of Alzheimers disease (AD) and dementia, but the biological mechanisms underlying these observations remain unclear. We investigated whether adult vaccination history is associated with AD-related and immune-related biomarker profiles in cognitively unimpaired individuals at increased familial risk for AD. MethodsThis exploratory study included 192 participants from the PREVENT-AD cohort. Adult vaccination and infection histories were collected using a structured questionnaire and examined in relation to plasma and cerebrospinal fluid (CSF) biomarkers. Adjusted regression models evaluated individual vaccine exposures, vaccination-profile breadth, broader proteomic signatures, CSF biomarkers, viral-history interactions, and psychological symptoms, with false-discovery-rate (FDR) correction applied for multiple testing. ResultsInfluenza, herpes zoster, pneumococcal, and Td/Tdap vaccination were not associated with FDR-significant differences in the principal plasma amyloid and tau biomarker panel. Hepatitis B vaccination was associated with lower plasma total tau/MAPT, p-tau181, and p-tau231 after correction within the AD biomarker panel, although these findings may reflect residual behavioral or healthcare-related confounding. Greater vaccination-profile breadth was associated with higher plasma NPTX1 ({beta} = 0.261, p = 0.007, q = 0.049), whereas its nominal association with a lower A{beta}42/A{beta}40 ratio did not survive FDR correction. Nominal herpes zoster associations with lower CSF A{beta}42 and pTau were similarly attenuated after correction. No robust FDR-significant associations emerged from viral-history interaction or psychological symptom analyses. ConclusionsAdult vaccination history was not associated with a broad plasma amyloid or tau signature in this asymptomatic, familial-risk cohort. However, the association between broader vaccination exposure and higher NPTX1 suggests a potentially distinct synaptic-related signal, while the hepatitis B findings identify additional hypothesis-generating tau-related associations. Longitudinal studies incorporating vaccine timing, infection burden, and repeated biomarker measurements are needed to determine whether vaccination influences biological pathways relevant to AD resilience.

What this study adds

Evidence grade: Moderate

This is a follow-up (cohort) study of 192 participants. These are preliminary observational biomarker findings, not evidence that vaccination prevents Alzheimer's disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Charland, S., Savard, M., Sarty, I., Dery, C., Villeneuve, S., Picard, C., et al. (2026). Adult Vaccination History and Plasma Biomarker Signatures in the Asymptomatic PREVENT-AD Cohort. medRxiv (preprint). https://doi.org/10.64898/2026.08.24.26361238

Vancouver

Charland S, Savard M, Sarty I, Dery C, Villeneuve S, Picard C, et al. Adult Vaccination History and Plasma Biomarker Signatures in the Asymptomatic PREVENT-AD Cohort. medRxiv (preprint). 2026. doi:10.64898/2026.08.24.26361238.

BibTeX

@article{charland2026-179bc140,
  author  = {Charland, S. and Savard, M. and Sarty, I. and Dery, C. and Villeneuve, S. and Picard, C. and Poirier, J.},
  title   = {{Adult Vaccination History and Plasma Biomarker Signatures in the Asymptomatic PREVENT-AD Cohort}},
  journal = {medRxiv (preprint)},
  year    = {2026},
  doi     = {10.64898/2026.08.24.26361238},
  url     = {https://doi.org/10.64898/2026.08.24.26361238}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Why it matters

In this exploratory study, influenza, herpes zoster, pneumococcal and Td/Tdap vaccination were not associated with significant differences in the main plasma amyloid and tau panel, while hepatitis B vaccination was associated with lower tau markers though possibly due to confounding. These are preliminary observational biomarker findings, not evidence that vaccination prevents Alzheimer's disease.

Study details

How this study scored 16/100
How this study's score is builtJournal tier 2 of 10; Journal's citation record 0 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 4 of 10; How recent 5 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 0 of 7; Citations per year 0 of 5; Impact for its field and year left out, no data; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 2 of 4; Institution's track record 1 of 3; Multicenter collaboration 0 of 3; Indexed in PubMed 1 of 2; Free to read 2 of 2. 32 of the 94 points it could be judged on, which is 34 of 100. Raw total 34 of 100, shown as 16 because this is not a peer-reviewed research article.raw total 34 of 100capped at 16 — hatched points do not count

Preprint — not yet peer-reviewed. It scored 34 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for effect reported and randomized / blinded because the record does not state it. We have no data on impact for its field and year, so that was left out: it earned 32 of the 94 points we could judge it on, which is 34 out of 100.

ComponentPointsWhy
Journal tier 2 / 10 Tier 4 — not a peer-reviewed journal (medRxiv (preprint))
Journal's citation record 0 / 4 Not a journal article, so the journal's record does not count
Study design 7 / 12 A longitudinal study following the same people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 4 / 10 Preprint — not yet peer-reviewed. Hosted on a preprint server.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 2 / 4 192 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 0 / 7 Cited 0 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.0 citations a year over 2 year(s) since 2026
Impact for its field and year — / 6 No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Sylvia Villeneuve: h-index 48 (OpenAlex, whole career)
Institution's track record 1 / 3 McGill University: institution h-index 1,373 (OpenAlex)
Multicenter collaboration 0 / 3 OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read 2 / 2 Free to read
Points 32 / 94 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 32 of the 94 points we could judge it on is 34 out of 100.
Total 34 / 100 Capped to 16 because this is not a peer-reviewed article.

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Related studies in Biomarkers from nearby years

Also tagged “cerebrospinal”

820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Biomarkers

See all studies in Biomarkers →